ArTS Archivio della ricerca di Trieste

GENERALI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.601
EU - Europa 12.303
AS - Asia 10.427
SA - Sud America 1.461
AF - Africa 307
OC - Oceania 40
Continente sconosciuto - Info sul continente non disponibili 7
Totale 47.146
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.338
PL - Polonia 4.924
SG - Singapore 3.834
CN - Cina 2.236
IT - Italia 1.775
HK - Hong Kong 1.313
SE - Svezia 1.154
BR - Brasile 1.142
VN - Vietnam 1.068
DE - Germania 728
FR - Francia 521
KR - Corea 499
RU - Federazione Russa 476
UA - Ucraina 472
NL - Olanda 464
FI - Finlandia 447
TR - Turchia 371
GB - Regno Unito 321
IN - India 275
IE - Irlanda 273
BG - Bulgaria 266
AR - Argentina 124
ES - Italia 114
MX - Messico 107
CA - Canada 94
JP - Giappone 85
BD - Bangladesh 81
MA - Marocco 81
IQ - Iraq 80
AT - Austria 75
ZA - Sudafrica 68
SA - Arabia Saudita 61
BE - Belgio 55
PK - Pakistan 53
ID - Indonesia 52
MY - Malesia 51
EC - Ecuador 45
IL - Israele 40
RO - Romania 40
AU - Australia 35
PH - Filippine 34
CL - Cile 33
TH - Thailandia 33
CO - Colombia 32
VE - Venezuela 32
CH - Svizzera 28
EG - Egitto 27
JO - Giordania 27
KE - Kenya 25
TN - Tunisia 25
IR - Iran 24
AZ - Azerbaigian 21
DZ - Algeria 21
TW - Taiwan 21
AE - Emirati Arabi Uniti 20
OM - Oman 19
PE - Perù 19
SN - Senegal 19
UZ - Uzbekistan 19
CZ - Repubblica Ceca 18
KZ - Kazakistan 18
PY - Paraguay 17
GR - Grecia 16
CR - Costa Rica 15
LT - Lituania 15
NP - Nepal 13
PT - Portogallo 13
EE - Estonia 12
AM - Armenia 11
HU - Ungheria 11
JM - Giamaica 11
DK - Danimarca 10
RS - Serbia 10
AL - Albania 8
CI - Costa d'Avorio 8
DO - Repubblica Dominicana 8
HN - Honduras 8
MD - Moldavia 8
NO - Norvegia 8
BH - Bahrain 7
ET - Etiopia 7
GE - Georgia 7
HR - Croazia 7
KG - Kirghizistan 7
UY - Uruguay 7
BO - Bolivia 6
LB - Libano 6
SK - Slovacchia (Repubblica Slovacca) 6
SY - Repubblica araba siriana 6
KW - Kuwait 5
LV - Lettonia 5
MN - Mongolia 5
MT - Malta 5
SI - Slovenia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AO - Angola 4
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
CY - Cipro 4
GT - Guatemala 4
Totale 47.070
Salva come PNG Salva come JPEG
Città #
Warsaw 4.651
Fairfield 2.614
Singapore 2.424
Ashburn 2.268
Woodbridge 1.992
Houston 1.635
Ann Arbor 1.351
Hong Kong 1.282
Chandler 1.115
Wilmington 1.102
Seattle 1.084
San Jose 1.042
Cambridge 958
Jacksonville 603
Trieste 485
Seoul 477
Princeton 472
Beijing 467
Boardman 457
Hefei 395
Santa Clara 351
Chicago 342
Izmir 312
Columbus 311
Dallas 309
Ho Chi Minh City 298
Amsterdam 287
Lauterbourg 279
Dublin 273
Sofia 261
Zgierz 226
Council Bluffs 221
Moscow 221
Hanoi 219
Los Angeles 199
Helsinki 198
The Dalles 190
San Diego 129
Frankfurt am Main 122
Milan 122
New York 117
Dong Ket 108
São Paulo 107
Buffalo 105
Munich 98
London 97
Dearborn 68
Tokyo 68
Falls Church 64
Nuremberg 61
Phoenix 60
Rome 57
Orem 54
Casablanca 52
Lappeenranta 52
Bremen 51
Redondo Beach 50
Shanghai 50
Tianjin 50
Da Nang 48
Rio de Janeiro 48
Düsseldorf 47
Guangzhou 45
Brussels 44
Turku 44
Vienna 42
Redwood City 39
Norwalk 38
Dongguan 37
Hangzhou 37
San Francisco 37
Chennai 34
Kerken 34
Brasília 33
Haiphong 33
Atlanta 32
Johannesburg 32
Boston 30
Duino-Aurisina 30
Toronto 30
Riyadh 29
Denver 28
Barcelona 27
Shenzhen 27
Venice 27
Des Moines 26
Redmond 26
Tel Aviv 26
Brooklyn 25
Mumbai 25
Nanjing 24
Stockholm 23
Baghdad 22
Belo Horizonte 22
Fremont 22
Jinan 22
Madrid 22
Montreal 22
New Delhi 22
Poplar 22
Totale 34.396
Salva come PNG Salva come JPEG
Nome #
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma 451
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration 426
Advances in systemic therapy for metastatic breast cancer: future perspectives 408
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial 398
NEODUCTGENESIS AS A PROGNOSTIC MARKER IN “DUCTAL” CARCINOMA IN SITU OF THE BREAST 398
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer 392
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? 387
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 384
Isolated testicular metastasis from prostate cancer 366
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study 365
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 363
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer 361
Designing a broad-spectrum integrative approach for cancer prevention and treatment 360
Current challenges in HER2-positive breast cancer 358
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition 352
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 352
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 342
Bevacizumab in small cell lung cancer 341
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 339
Characterization of MTAP gene expression in breast cancer patients and cell lines 338
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer 334
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 333
Broad targeting of angiogenesis for cancer prevention and therapy 331
Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study 321
Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? 318
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts 316
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes 314
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 307
Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HEeR2- advanced breast cancer 304
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma 303
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 299
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma 283
The relevance of chemobrain in breast cancer survivors: An Italian exploratory study to measure incidence and psycho-social impact 276
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 274
Apatinib for the treatment of gastric cancer 273
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit 272
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers 271
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. 270
Advances in systemic therapy for malignant mesothelioma: Future perspectives 268
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 263
Lenvatinib for the treatment of renal cell carcinoma 263
Inhibitors of Tumor Angiogenesis 255
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 245
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 241
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 240
The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis 237
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis 236
PROGNOSTIC ROLE OF TUMOR INFILTRATING LYMPHOCITES (TILS) IN EPITHELIOID PLEURAL MESOTHELIOMA 235
CDK4/6 inhibitors in HER2-positive breast cancer 233
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis 230
Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste 228
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment 226
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study 221
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR 220
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 219
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 217
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 215
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? 215
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data 207
Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers 207
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 205
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 205
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET) 202
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 198
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? 197
Ibrutinib: from bench side to clinical implications 196
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 194
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? 193
High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer 192
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 191
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer 190
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 190
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making 188
RNA disruption and drug response in breast cancer primary systemic therapy 185
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 183
Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials 181
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 181
"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? 179
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer 179
Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer 177
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 177
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report 176
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 176
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights 175
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy 174
Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis 174
Granular cell tumor of the breast: a multidisciplinary challenge 174
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer 173
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 173
Evaluation of circulating cell-free DNA and its integrity as a potential predictive biomarker of breast cancer onset: A pilot study 173
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer 172
Impact of psychosocial, behavioral and lifestyle factors on subjective cognitive complaints and perceived quality of life in a large cohort of Italian breast cancer patients 171
Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials 171
Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? 170
Gene expression profiling in breast cancer: A clinical perspective 167
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: A rhythmometric analysis 167
Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients 167
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 164
Neoadjuvant model in cancer treatment: From clinical opportunity to health-care utility 164
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 164
Totale 25.229
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.894
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.894
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021890 0 0 0 0 0 0 0 0 0 349 184 357
2021/20222.804 163 409 197 173 39 197 134 107 380 380 172 453
2022/20233.528 335 361 295 433 368 653 54 313 427 39 178 72
2023/20242.825 120 364 163 188 162 226 476 594 24 122 217 169
2024/20256.728 96 524 834 424 589 943 274 378 769 750 548 599
2025/202612.769 1.205 866 879 1.002 1.289 1.174 2.215 569 1.717 1.853 0 0
Totale 48.176